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Background: Breast cancer today has many established risk factors, both genetic and environmental, but these risk
factors by themselves explain only part of the total cancer incidence. We have investigated potential interactions
between certain known genetic and phenotypic risk factors, specifically nine single nucleotide polymorphisms
(SNPs) and height, body mass index (BMI) and hormone replacement therapy (HRT).
Methods: We analyzed samples from three different study populations: two prospectively followed Swedish
cohorts and one Icelandic case–control study. Totally 2884 invasive breast cancer cases and 4508 controls were
analysed in the study. Genotypes were determined using Mass spectrometry-Maldi-TOF and phenotypic variables
were derived from measurements and/or questionnaires. Odds Ratios and 95% confidence intervals were calculated
using unconditional logistic regression with the inclusion of an interaction term in the logistic regression model.
Results: One SNP (rs851987 in ESR1) tended to interact with height, with an increasingly protective effect of the
major allele in taller women (p = 0.007) and rs13281615 (on 8q24) tended to confer risk only in non users of HRT
(p-for interaction = 0.03). There were no significant interactions after correction for multiple testing.
Conclusions: We conclude that much larger sample sets would be necessary to demonstrate interactions between
low-risk genetic polymorphisms and the phenotypic variables height, BMI and HRT on the risk for breast cancer.
However the present hypothesis-generating study has identified tendencies that would be of interest to evaluate
for gene-environment interactions in independent materials.Background
Genome wide association studies (GWAS), have discov-
ered several new genetic polymorphisms affecting breast
cancer risk [1-3]. Even though these individual risk-
factors each confer quite small increases in risk, a posi-
tive association is seen between the number of risk
alleles carried and risk for breast cancer [4,5].
The phenotypic variables height, body mass index
(BMI) and use of hormone replacement therapy (HRT)
reflect to varying degrees genetic background and
environmental exposure. Both height and BMI have
previously been shown to associate with breast cancer* Correspondence: joyce.carlson@med.lu.se
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reproduction in any medium, provided the or[6,7]. Increase in height has been shown to yield a pro-
portional increase in breast cancer risk and obese
women have a greater risk to contract postmenopausal
breast cancer. Increased risk is also established for
users of HRT [7], which has been speculated to inter-
act with low-risk polymorphisms in the FGFR2 gene
[8,9].
Although there have been investigations on gene-
environment interactions in breast cancer [10], this area
remains to a large extent unexplored.
The aim of this study was to investigate if height, BMI
and HRT modify the genetic predisposition to breast
cancer conferred by reported low-risk polymorphisms.
For this purpose we had access to two well defined
Swedish population based cohorts as well as an Icelandic
hospital based case control study, altogether 7738 samples
(3016 cases and 4722 controls).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study populations
The samples originate from two Swedish independent
population based cohorts; the Malmö Diet and Cancer
Study (MDCS) from southern Sweden and the North
Sweden Health and Disease Study (NSHDS), together
comprising 2410 incident cases and 3829 controls. The
third sample collection was an Icelandic population-based
case control study including 866 cases and 948 controls.
Written informed consent was retrieved from all women
prior to donating their samples. All cohorts have been
described previously [11] and are briefly presented below.
MDCS
The Malmö Diet and Cancer Study (MDCS) is a pro-
spective cohort study initiated in 1991. Totally it com-
prises 17035 female residents of Malmö Sweden
recruited between 1991 and 1996 [12,13]. By linkage to
the national cancer registry until 31st of December 2007,
730 incident cases of invasive breast cancer were identi-
fied among MDCS participants. They were matched to
1460 controls from the same cohort according to sex,
age (+/− 6 months), and date of sampling at baseline
(+/− 2 months). Median age at breast cancer diagnosis
was 65 years (range 45–84). Thirty-three cases and 65
controls were ≤50 years of age at time of diagnosis.
The MDCS and the present analyses were approved by
the Ethical Committee at Lund University (LU 51–90,
Dnr 652/2005 and Dnr 2009/682).
NSHDS
The Northern Sweden Health and Disease Study
(NSHDS) include the Västerbotten Intervention Program
(VIP), and the Mammography Screening Program
(MSP), initiated in 1985 and 1995 respectively. Partici-
pants in the VIP are screened at 40, 50 and 60 years of
age and mammography screening and blood sampling is
performed among women between 50 and 69 years of
age [14]. Through linkage with the cancer register up to
December 31st, 2008, 1680 prospective cases of invasive
breast cancer (median age 56 years, range 27–95) were
identified. They were matched to 2314 controls by sex,
age (+/− 6 months), and date of sampling at baseline
(+/− 2 months), (474 cases and 606 controls ≤50 years
of age). Information on HRT use was available for 1420
of these cases.
The NSHDS and the present analyses were approved
by the Ethical Committee at Umeå University (Dnr:
2010-147-132 and 07–141).
ICELAND
The Icelandic samples were collected between 1998 and
2006 and represent 45–77% of all Icelandic women with
invasive breast cancer diagnosed between 1957 and2007. The rate of participation varied somewhat depend-
ing on the year of diagnosis and was highest between
1999 and 2003 (77%). Unmatched controls were col-
lected between 2000 and 2004, either from women who
participated in the population-based cervical or breast
cancer screening program and found free of breast can-
cer or from older women in retirement homes who had
not been diagnosed with breast cancer, to generally
reflect the ages of the cases. By linkage to the Icelandic
cancer registry in 2008 we identified cases diagnosed
before 31st of December 2007. Totally 866 cases (median
age 55 years, range 22–98, 314 ≤ 50 years) and 948 con-
trols (median age 58 years, range 25–102, 256≤ 50 years)
had DNA available and were eligible to us.
The use of these samples was approved by the data protec-
tion law (200605037), and the Icelandic Science Ethics Com-
mittee (VSNb2006050001/03-16 and VSNb2005070008/
03-16).
Data collection
Participants in both Swedish cohorts completed a ques-
tionnaire providing information about current medica-
tion at the time of recruitment. Participants in the
NSHDS also provided information about height and
weight while a trained nurse at the study centre mea-
sured height and weight, for participants in MDCS [15].
The Icelandic women answered questions about height,
weight and HRT use when they attended the Detection
Cancer Clinic (breast cancer mammography or cervical
screening) at the Icelandic Cancer Society. The women
answered questions at least every tenth year and the most
recent answers were used in the study. For the Icelandic
cases only data collected prior to breast cancer diagnosis
was used. BMI for all participants was calculated as kg/m2.
SNP selection
All loci identified by GWAS to be associated with breast
cancer and published before June 31st 2007 were initially
included in the study [1-3]. Individual SNPs were
selected from the publications by Easton et al. and Sta-
cey et al. This primary selection included 10 SNPs,
as well as one SNP in CASP8 identified using the candi-
date gene approach [16]. Two SNPs selected from our
own candidate CpG SNP study [11] were also included
making a total of 13 SNPs (Figure 1).
Assay design and genotyping
Eleven SNPs, combined by the SEQUENOM Mass-
ARRAYW Designer software in a single multiplex assay
were analyzed on a MALDI-TOF mass spectrometer
(SEQUENOM MassArray) using standard iPLEX reagents
and protocol (SEQUENOM) and 10 ng DNA as PCR
template. Primer sets were from Metabion (Martinsried,
Germany).
1.0
Gene/position SNP rs number Per allele OR (95%CI) p-trend Per allele OR (95%CI) p-trend
FGFR2 rs2981582 1.24 (1.16-1.33) 2.34E-10 1.22 (1.14-1.30) 1.34E-08
MAP3K1 rs889312 1.16 (1.08-1.25) 5.74E-05 1.17 (1.08-1.26) 4.26E-05
TOX3 rs3803662 1.15 (1.07-1.24) 1.19E-04 1.16 (1.08-1.25) 5.34E-05
TOX3 rs12443621 1.14 (1.07-1.22) 7.13E-05 1.14 (1.07-1.22) 7.40E-05
ESR1 rs7766585 1.15 (1.05-1.26) 3.30E-03 1.16 (1.05-1.27) 2.66E-03
2q35 rs13387042 1.09 (1.02-1.17) 0.01 1.10 (1.03-1.17) 7.47E-03
LSP1 rs3817198 1.10 (1.02-1.18) 8.53E-03 1.10 (1.02-1.18) 8.65E-03
8q24 rs13281615 1.09 (1.02-1.17) 8.45E-03 1.08 (1.01-1.15) 0.03
TOX3 rs8051542 1.07 (1.00-1.15) 0.04 1.08 (1.01-1.15) 0.03
HCN1 rs981782 0.93 (0.87-1.00) 0.04 0.93 (0.87-1.00) 0.04
ESR1 rs851987 0.94 (0.87-1.01) 0.09 0.93 (0.86-1.00) 0.06
CASP8 rs1045485 0.95 (0.86-1.06) 0.36 0.95 (0.86-1.05) 0.33
5q11 rs30099 1.00 (0.89-1.13) 0.99 1.03 (0.91-1.17) 0.64
Unadjusted Adjusted for age and study-population
0.8 1.4
Figure 1 Odds Ratios and Confidence Intervals for all SNPs. All 13 primary polymorphisms and their respective OR and p-value in this sample
set. Squares represent OR and brackets represent 95% CI for samples adjusted for age and study population. A subset of previously published
data [11].
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separate TaqManW “assay by design” genotyping assay
on a 7900HT instrument, using Master mix No UNG
from Applied Biosystems according to the manufac-
turer’s instructions. Reaction mixtures (6μL) containing
2 ng of DNA template, primers (rs2981582 forward pri-
mer 5′-CAG CAC TCA TCG CCA CTT AAT G-3′, re-
verse primer 5′-GAC ACC ACT CGG ACT GCT-3′,
and probes 5′-VIC-TCT CCG CAA ACA GG-MGB-3′
and 5′-FAM-CTC TCC ACA AAC AGG-MGB-3′)
(rs1045485 forward primer 5′-ACC ACG ACC TTT
GAA GAG CTT -3′, reverse primer 5′-ACT GTG
GTC CAT GAG TTG GTA GAT-3′, and probes 5′-VIC-
CCC CAC GAT GAC TG-MGB-3′ and 5′-FAM-CCC
CAC CAT GAC TG-MGB-3′) were subjected to two
minutes at 50°C and ten minutes at 95°C, followed by 50
PCR cycles of 95°C for 15 seconds and 60°C for one
minute.
Three percent of the samples from NSHDS and five
percent of the Icelandic samples were included as
blinded duplicates for quality control purposes.
Statistical analysis
Individual samples producing results in< 80% of the
assays were excluded prior to statistical analyses toeliminate samples with low-quality DNA. Genotype data
from control samples were tested for consistency with
Hardy-Weinberg equilibrium (HWE) using a χ² p-value
cutpoint of 0.001. Unconditional logistic regression was
used to measure the independent association between
each genotype and breast cancer, with Odds ratios and
95% confidence intervals (CI) estimated for each geno-
type. Per allele OR (p-trend) was calculated using 0, 1 or
2 copies of the minor allele (a) as a continuous variable.
OR and 95% CI were calculated between each pheno-
typic variable (Height, BMI and HRT) and risk for breast
cancer, these results were also age adjusted. Data was
then stratified into tertiles according to height (<162 cm,
162–166 am and >166 cm), and into subcategories of
BMI according to the WHO guidelines (Normal weight:
18.5-25, Overweight: 25–30 and Obese> 30). For HRT
subjects data was stratified according to reported “non
use” and “current use”. The current users were further
divided into users of only estrogen or combined hor-
mones. OR and 95%CI were calculated for each variable
(Height, BMI and HRT) and risk for breast cancer.
A p-value for interaction was estimated for each pair
of genotype/phenotype and a value of less than 0.05 was
considered statistically significant. As adjustment for mul-
tiple comparisons this value was divided by the number
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x 3 =24) and the new significance threshold was 0.002.
All results were adjusted for age and study population.
Results
Of the initial 7738 samples selected for the project 7392
(95.5%) were successfully retrieved and genotyped for ≥
80% of the SNPs. All SNPs had a genotyping success
rate> 94%, with an average of 98.0%. Results of all
200 analyses performed on duplicate samples were in
100% concordance.
Per allele OR for each independent SNP is presented
in Figure 1. Ten of the SNPs were significant (p< 0.05)
in our material with rs2981852 (FGFR2), rs889312
(MAP3K1) and rs3803662 (TOX3) exhibiting the highest
ORs. Two of the SNPs had p-values >0.1 (rs1045485
[CASP8] and rs30099 [5q11]) and were excluded from
further analysis.
Three of the SNPs in TOX3 (rs3803662, rs12443621
and rs8051542) exhibited linkage (results not shown)
as has previously been reported [1,4]. Rs12443621 and
rs80515442 were therefore excluded from further analysis.
Independent analysis of risk association with each
phenotypic variable (height, BMI, HRT) within the entire
study population revealed a significantly increased risk
of breast cancer for individuals >162 cm compared to
shorter women, this association was weakened following
age adjustment. No statistical significant correlation
between BMI and risk for breast cancer was found in
this population. For current use vs. non-use of HRT, aTable 1 Environmental risk factors (MDCS, NSHDS and ICELAN
Risk factor Categories MDCS NSHD
Count OR* Count
Case/Control (95% CI) Case/Control
All individuals
BMI Normal Weight 334/695 1 637/997
Over weight 237/450 1.26 (1.02-1.56) 439/701 0.9
Obese 95/194 1.25 (0.94-1.66) 167/286 0.9
Height <162 cm 207/471 1 398/722
162-166 cm 233/443 1.03 (0.81-1.30) 445/657 1.2
>166 cm 233/448 0.93 (0.73-1.18) 436/640 1.2
> 50 years
HRT Non users 341/806 1 777/1320
Current users 181/256 1.26 (0.99-1.61) 186/295 1.0
BMI Normal Weight 322/694 1 400/682
Over weight 232/449 1.26 (1.02-1.57) 320/504 1.0
Obese 95/194 1.26 (0.94-1.68) 130/205 1.1
Height <162 cm 205/471 1 283/534
162-166 cm 224/442 1.02 (0.81-1.29) 311/458 1.2
>166 cm 227/447 0.94 (0.74-1.19) 279/421 1.2
*Adjusted for age.significantly increased risk was seen for users, OR (95%
CI) 1.24 (1.08-1.42), which remained after adjustment
for age (Table 1).
Stratified analysis and interactions
After stratification by height (as described in materials
and methods), one SNP (rs851987) in ESR1 had a
p-interaction= 0.007 with height, with an increasingly
protective effect of the major allele in taller women, but
it did not pass the threshold for multiple comparisons
(p = 0.002) (Table 2).
None of the SNPs showed any tendencies towards
significant interactions after stratification according to
BMI (Table 3).
Following stratification of genotypes according to
reported current use or non-use of hormone replace-
ment therapy, rs13281615 (8q24) was significant only
in non users of HRT with a p-for interaction of 0.03,
indicating borderline significance (Table 4).
Discussion
In this study we have explored interactions between
reported genetic risk factors for breast cancer and the
three additional established risk factors; height, BMI and
HRT in 2884 cases and 4508 controls. The strongest ten-
dency for interaction found was that between height and
rs851987 in ESR1, although it did not pass the thresh-
old for multiple comparisons. Taller women carrying the
T-allele appeared to have reduced breast cancer risk
(p for interaction=0.007) (Table 2). Rs851987 was describedD)
S ICELAND TOTAL
OR* Count OR* Count OR*
(95% CI) Case/Control (95% CI) Case/Control (95% CI)
1 361/326 1 1332/2018 1
9 (0.84-1.15) 241/312 0.76 (0.60-0.96) 917/1463 1.00 (0.90-1.12)
1 (0.74-1.14) 112/139 0.79 (0.59-1.07) 374/619 0.97 (0.84-1.13)
1 171/173 1 776/1366 1
1 (1.02-1.44) 289/307 0.92 (0.70-1.20) 967/1407 1.15 (1.02-1.30)
1 (1.01-1.44) 354/414 0.78 (0.60-1.02) 1023/1502 1.09 (0.97-1.23)
1 66/286 1 1184/2412 1
9 (0.89-1.34) 105/225 2.06 (1.45-2.95) 424/776 1.22 (1.07-1.39)
1 189/217 1 911/1593 1
9 (0.91-1.32) 188/255 0.85 (0.65-1.12) 740/1208 1.12 (0.99-1.26)
0 (0.85-1.41) 86/109 0.91 (0.65-1.29) 311/508 1.13 (0.96-1.34)
1 125/136 1 613/1141 1
6 (1.03-1.55) 198/244 0.88 (0.64-1.19) 733/1144 1.13 (0.99-1.30)
2 (0.99-1.51) 199/274 0.78 (0.57-1.06) 705/1142 1.05 (0.92-1.21)
Table 2 OR adjusted for Age and Study Population, stratified by Height
SNP rs nr Genotype p-value for
interaction
All individuals Height <162.0 cm Height 162.0-166.0 cm Height >166.0 cm
case/contr: 2869/4480 case/control: 776/1366 case/control: 967/1407 case/control: 1023/1502
OR 95%CI p-trend OR 95%CI p-trend OR 95%CI p-trend OR 95%CI p-trend
FGFR2 2981582 AA 1 1 1 1
Aa 1.23 (1.10-1.37) 1.35 (1.10-1.66) 1.33 (1.10-1.61) 1.07 (0.89-1.28)
aa 1.48 (1.29-1.69) 1.57 (1.21-2.02) 1.56 (1.22-1.99) 1.32 (1.04-1.67)
Per Allele 0,41 1.22 (1.14-1.30) 1.34E-08 1.26 (1.11-1.43) 2.86E-04 1.26 (1.12-1.42) 1.65E-04 1.14 (1.01-1.28) 0.03
TNR09 3803662 AA 1 1 1 1
Aa 1.14 (1.03-1.26) 1.09 (0.90-1.32) 1.23 (1.03-1.47) 1.15 (0.97-1.36)
aa 1.39 (1.17-1.67) 1.37 (1.00-1.87) 1.37 (1.00-1.89) 1.42 (1.03-1.95)
Per Allele 0,91 1.16 (1.08-1.25) 5.34E-05 1.14 (1.00-1.31) 0.06 1.20 (1.05-1.37) 6.78E-03 1.17 (1.03-1.33) 0.02
MAP3K1 889312 AA 1 1 1 1
Aa 1.21 (1.09-1.34) 1.29 (1.06-1.55) 1.14 (0.95-1.36) 1.18 (1.00-1.40)
aa 1.29 (1.09-1.54) 1.31 (0.95-1.81) 1.05 (0.76-1.45) 1.53 (1.14-2.06)
Per Allele 0,45 1.17 (1.08-1.26) 4.26E-05 1.20 (1.04-1.37) 9.92E-03 1.07 (0.94-1.22) 0.29 1.22 (1.07-1.38) 2.20E-03
8q24 13281615 AA 1 1 1 1
Aa 1.12 (1.00-1.24) 1.21 (0.98-1.48) 1.07 (0.89-1.29) 1.12 (0.93-1.34)
aa 1.15 (1.00-1.32) 1.24 (0.96-1.60) 1.17 (0.92-1.49) 1.09 (0.87-1.38)
Per Allele 0,90 1.08 (1.01-1.15) 0.03 1.12 (0.99-1.27) 0.07 1.08 (0.96-1.22) 0.20 1.06 (0.94-1.18) 0.35
LSP1 3817198 AA 1 1 1 1
Aa 1.12 (1.02-1.24) 1.19 (0.99-1.45) 1.08 (0.90-1.28) 1.08 (0.91-1.28)
aa 1.19 (1.00-1.40) 1.50 (1.11-2.02) 1.14 (0.84-1.55) 1.04 (0.79-1.38)
Per Allele 0,48 1.10 (1.02-1.18) 8.65E-03 1.21 (1.06-1.39) 4.41E-03 1.07 (0.94-1.22) 0.29 1.04 (0.92-1.18) 0.50
2q35 AA 1 1 1 1
Aa 1.05 (0.93-1.19) 0.90 (0.72-1.14) 1.21 (0.98-1.50) 0.97 (0.79-1.19)
aa 1.20 (1.05-1.37) 1.09 (0.85-1.40) 1.28 (1.01-1.63) 1.21 (0.96-1.52)
Per Allele 0,38 1.10 (1.03-1.17) 7.47E-03 1.05 (0.93-1.19) 0.43 1.13 (1.00-1.27) 0.04 1.10 (0.98-1.23) 0.11
ESR1 7766585 AA 1 1 1 1
Aa 1.23 (1.10-1.37) 1.12 (0.90-1.38) 1.26 (1.03-1.53) 1.25 (1.04-1.50)
aa 1.02 (0.74-1.41) 0.83 (0.43-1.58) 1.21 (0.69-2.13) 0.98 (0.57-1.66)
Per Allele 0,83 1.16 (1.05-1.27) 2.66E-03 1.05 (0.88-1.26) 0.60 1.20 (1.02-1.42) 0.03 1.16 (0.99-1.36) 0.06
HCN1 981782 AA 1 1 1 1
Aa 0.97 (0.87-1.09) 0.92 (0.74-1.14) 1.03 (0.84-1.26) 1.00 (0.82-1.21)
aa 0.86 (0.75-0.99) 0.91 (0.70-1.18) 0.96 (0.75-1.22) 0.77 (0.61-0.98)
Per Allele 0,51 0.93 (0.87-1.00) 0.04 0.95 (0.83-1.08) 0.44 0.98 (0.87-1.11) 0.73 0.88 (0.78-0.99) 0.04
ESR1 851987 AA 1 1 1 1
Aa 0.91 (0.82-1.02) 0.96 (0.78-1.17) 0.92 (0.76-1.11) 0.87 (0.73-1.05)
aa 0.88 (0.74-1.05) 1.44 (1.06-1.95) 0.69 (0.50-0.96) 0.71 (0.52-0.98)
Per Allele 6.70E-03 0.93 (0.86-1.00) 0.06 1.12 (0.97-1.28) 0.12 0.86 (0.75-0.99) 0.04 0.86 (0.75-0.98) 0.02
None of the SNPs showed any tendencies towards significant interactions after stratification according to BMI (Table 3).
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the extended promoter region of ESR1, about 3.7 kb 5′
of exon F. Exon F and its promoter were originally
described by Thompson et al. [17] and have later been
shown to affect the level of ESR1 expression inosteoblastic cells [18,19]. A potential association between
ESR1 and height has been described in another study
comprising adult males from two Swedish population
cohorts [20]. Mutations in ESR1 have been reported
to delay fusion of the epiphyseal plates at puberty [21],
Table 3 OR adjusted for Age and Study Population, stratified by BMI
SNP rs nr Genotype p-value for
interaction
All individuals Normal Weigth Over Weight Obese
BMI = 18.5-24.99 BMI = 25.00-29.99 BMI≥ 30
case/contr: 2869/4480 case/control: 1332/2018 case/control: 917/1463 case/control: 374/619
OR 95%CI p-trend OR 95%CI p-trend OR 95%CI p-trend OR 95%CI p-trend
FGFR2 2981582 AA 1 1 1 1
Aa 1.23 (1.10-1.37) 1.26 (1.07-1.48) 1.18 (0.97-1.42) 1.08 (0.80-1.46)
aa 1.48 (1.29-1.69) 1.46 (1.18-1.80) 1.57 (1.24-1.99) 1.14 (0.78-1.66)
Per Allele 0.59 1.22 (1.14-1.30) 1.34E-08 1.21 (1.10-1.35) 2.03E-04 1.25 (1.11-1.40) 2.20E-04 1.07 (0.89-1.29) 0.49
TNR09 3803662 AA 1 1 1 1
Aa 1.14 (1.03-1.26) 1.16 (1.00-1.35) 1.13 (0.94-1.34) 1.27 (0.97-1.67)
aa 1.39 (1.17-1.67) 1.44 (1.10-1.89) 1.21 (0.89-1.65) 1.72 (1.07-2.78)
Per Allele 0.72 1.16 (1.08-1.25) 5.34E-05 1.18 (1.06-1.32) 2.88E-03 1.11 (0.98-1.26) 0.11 1.30 (1.06-1.58) 0.01
MAP3K1 889312 AA 1 1 1 1
Aa 1.21 (1.09-1.34) 1.15 (0.99-1.33) 1.33 (1.11-1.58) 1.21 (0.92-1.59)
aa 1.29 (1.09-1.54) 1.22 (0.94-1.59) 1.63 (1.20-2.22) 1.22 (0.76-1.97)
Per Allele 0.47 1.17 (1.08-1.26) 4.26E-05 1.12 (1.01-1.25) 0.04 1.30 (1.14-1.48) 8.64E-05 1.15 (0.94-1.40) 0.18
8q24 13281615 AA 1 1 1 1
Aa 1.12 (1.00-1.24) 1.18 (1.01-1.39) 1.04 (0.86-1.25) 1.13 (0.84-1.52)
aa 1.15 (1.00-1.32) 1.22 (0.99-1.49) 1.14 (0.90-1.45) 1.10 (0.75-1.60)
Per Allele 0.82 1.08 (1.01-1.15) 0.03 1.11 (1.01-1.23) 0.04 1.06 (0.95-1.20) 0.30 1.06 (0.88-1.27) 0.54
LSP1 3817198 AA 1 1 1 1
Aa 1.12 (1.02-1.24) 1.16 (0.99-1.34) 1.11 (0.93-1.33) 0.94 (0.72-1.24)
aa 1.19 (1.00-1.40) 1.41 (1.10-1.81) 1.06 (0.80-1.42) 0.83 (0.50-1.38)
Per Allele 0.35 1.10 (1.02-1.18) 8.65E-03 1.18 (1.06-1.31) 3.22E-03 1.06 (0.93-1.20) 0.38 0.93 (0.75-1.14) 0.47
2q35 AA 1 1 1 1
Aa 1.05 (0.93-1.19) 1.04 (0.87-1.24) 1.00 (0.81-1.23) 1.12 (0.80-1.58)
aa 1.20 (1.05-1.37) 1.09 (0.89-1.33) 1.28 (1.01-1.61) 1.38 (0.94-2.03)
Per Allele 0.63 1.10 (1.03-1.17) 7.47E-03 1.04 (0.94-1.15) 0.40 1.13 (1.01-1.27) 0.04 1.18 (0.97-1.43) 0.09
ESR1 7766585 AA 1 1 1 1
Aa 1.23 (1.10-1.37) 1.29 (1.09-1.52) 1.18 (0.97-1.43) 1.07 (0.79-1.44)
aa 1.02 (0.74-1.41) 0.98 (0.60-1.61) 1.27 (0.76-2.14) 0.51 (0.18-1.41)
Per Allele 0.47 1.16 (1.05-1.27) 2.66E-03 1.19 (1.03-1.37) 0.02 1.16 (0.99-1.37) 0.07 0.96 (0.74-1.24) 0.75
HCN1 981782 AA 1 1 1 1
Aa 0.97 (0.87-1.09) 1.04 (0.87-1.24) 1.01 (0.82-1.23) 0.87 (0.63-1.20)
aa 0.86 (0.75-0.99) 0.84 (0.68-1.04) 1.00 (0.79-1.28) 0.87 (0.59-1.27)
Per Allele 0.50 0.93 (0.87-1.00) 0.04 0.92 (0.83-1.02) 0.13 1.00 (0.89-1.13) 0.98 0.93 (0.77-1.13) 0.46
ESR1 851987 AA 1 1 1 1
Aa 0.91 (0.82-1.02) 0.91 (0.78-1.06) 0.97 (0.80-1.17) 0.92 (0.69-1.22)
aa 0.88 (0.74-1.05) 0.92 (0.71-1.20) 0.83 (0.61-1.13) 0.76 (0.46-1.25)
Per Allele 0.89 0.93 (0.86-1.00) 0.06 0.94 (0.84-1.05) 0.29 0.93 (0.81-1.07) 0.30 0.89 (0.72-1.10) 0.28
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this biological effect or is linked to other causal variants.
One SNP (rs13281615 in 8q4) first described by
Easton et al. [1] showed a weak tendency for interaction
with use of HRT. The minor allele seems to conferincreased breast cancer risk in HRT non-users but no
excess risk in current users. The association in non-
users is strong with a per-allele OR (95%CI) of 1.20
(1.10-1.31) (p-trend = 6.1 × 10-5) compared to a per-allele
OR (95%CI) of 1.08 (1.01-1.15) (p-trend = 0.03) in all
Table 4 OR adjusted for Age and Study Population, stratified by HRT
SNP rs nr Genotype p-value for
interaction
All individuals* HRT Non Users* HRT Current Users* HRT Estrogen* HRT Comb*
case/contr: 2869/4480 case/contr: 1536/2949 case/contr: 494/800 case/contr: 185/324 case/contr:298/455
OR 95%CI p-trend OR 95%CI p-trend OR 95%CI p-trend OR 95%CI p-trend OR 95%CI p-trend
FGFR2 2981582 AA 1 1 1 1 1
Aa 1.23 (1.10-1.37) 1.22 (1.06-1.41) 1.16 (0.89-1.50) 1.15 (0.75-1.75) 1.17 (0.83-1.65)
aa 1.48 (1.29-1.69) 1.55 (1.29-1.89) 1.63 (1.17-2.26) 1.44 (0.86-2.42) 1.87 (1.21-2.89)
Per Allele 0,83 1.22 (1.14-1.30) 1.34E-08 1.24 (1.14-1.36) 2.04E-06 1.26 (1.07-1.49) 4.83E-03 1.20 (0.92-1.55) 0.18 1.34 (1.08-1.66) 7.30E-03
TNRC9 3803662 AA 1 1 1 1 1
Aa 1.14 (1.03-1.26) 1.15 (1.01-1.31) 1.17 (0.91-1.49) 1.31 (0.89-1.94) 1.13 (0.83-1.56)
aa 1.39 (1.17-1.67) 1.48 (1.18-1.86) 1.47 (0.96-2.27) 1.56 (0.79-3.11) 1.53 (0.86-2.69)
Per Allele 0,98 1.16 (1.08-1.25) 5.34E-05 1.19 (1.08-1.31) 3.74E-04 1.19 (1.00-1.43) 0.05 1.28 (0.96-1.70) 0.09 1.19 (0.94-1.51) 0.15
MAP3K1 889312 AA 1 1 1 1 1
Aa 1.21 (1.09-1.34) 1.27 (1.11-1.45) 1.04 (0.82-1.32) 0.87 (0.59-1.29) 1.13 (0.82-1.54)
aa 1.29 (1.09-1.54) 1.20 (0.95-1.53) 1.54 (1.02-2.33) 1.81 (0.98-3.33) 1.31 (0.74-2.33)
Per Allele 0,12 1.17 (1.08-1.26) 4.26E-05 1.17 (1.06-1.29) 1.90E-03 1.15 (0.97-1.38) 0.11 1.16 (0.88-1.52) 0.28 1.14 (0.90-1.44) 0.29
8q24 13281615 AA 1 1 1 1 1
Aa 1.12 (1.00-1.24) 1.20 (1.04-1.39) 1.05 (0.81-1.34) 0.90 (0.60-1.36) 1.10 (0.80-1.53)
aa 1.15 (1.00-1.32) 1.43 (1.20-1.71) 0.86 (0.61-1.20) 0.88 (0.52-1.51) 0.84 (0.53-1.32)
Per Allele 0,03 1.08 (1.01-1.15) 0.03 1.20 (1.10-1.31) 6.10E-05 0.95 (0.81-1.12) 0.52 0.93 (0.72-1.22) 0.61 0.95 (0.77-1.18) 0.67
LSP1 3817198 AA 1 1 1 1 1
Aa 1.12 (1.02-1.24) 1.13 (0.99-1.29) 1.29 (1.01-1.65) 1.32 (0.89-1.94) 1.30 (0.95-1.80)
aa 1.19 (1.00-1.40) 1.06 (0.85-1.31) 1.68 (1.12-2.53) 1.19 (0.61-2.33) 2.35 (1.37-4.03)
Per Allele 0,13 1.10 (1.02-1.18) 8.65E-03 1.06 (0.97-1.17) 0.21 1.30 (1.09-1.55) 4.07E-03 1.18 (0.89-1.56) 0.26 1.44 (1.14-1.82) 2.16E-03
2q35 AA 1 1 1 1 1
Aa 1.05 (0.93-1.19) 1.05 (0.89-1.23) 0.95 (0.72-1.27) 0.77 (0.48-1.25) 1.13 (0.78-1.63)
aa 1.20 (1.05-1.37) 1.15 (0.97-1.38) 1.20 (0.87-1.67) 1.26 (0.75-2.10) 1.20 (0.78-1.85)






















Table 4 OR adjusted for Age and Study Population, stratified by HRT (Continued)
ESR1 7766585 AA 1 1 1 1 1
Aa 1.23 (1.10-1.37) 1.23 (1.07-1.43) 1.05 (0.81-1.36) 1.31 (0.85-2.03) 0.88 (0.63-1.23)
aa 1.02 (0.74-1.41) 1.01 (0.67-1.53) 1.29 (0.61-2.73) 1.43 (0.52-3.93) 0.86 (0.26-2.81)
Per Allele 0,47 1.16 (1.05-1.27) 2.66E-03 1.15 (1.02-1.31) 0.02 1.07 (0.86-1.34) 0.53 1.26 (0.89-1.79) 0.19 0.89 (0.66-1.21) 0.46
HCN1 981782 AA 1 1 1 1 1
Aa 0.97 (0.87-1.09) 0.88 (0.76-1.02) 1.15 (0.86-1.53) 0.88 (0.57-1.38) 1.34 (0.92-1.96)
aa 0.86 (0.75-0.99) 0.80 (0.66-0.95) 0.93 (0.66-1.31) 0.74 (0.43-1.28) 1.05 (0.67-1.64)
Per Allele 0,26 0.93 (0.87-1.00) 0.04 0.89 (0.81-0.98) 0.01 0.97 (0.82-1.14) 0.70 0.86 (0.66-1.13) 0.28 1.02 (0.82-1.27) 0.84
ESR1 851987 AA 1 1 1 1 1
Aa 0.91 (0.82-1.02) 0.94 (0.82-1.07) 0.80 (0.62-1.04) 0.94 (0.63-1.43) 0.73 (0.52-1.03)
aa 0.88 (0.74-1.05) 0.90 (0.72-1.13) 0.93 (0.62-1.42) 0.88 (0.46-1.68) 0.96 (0.54-1.69)






















Harlid et al. BMC Women's Health 2012, 12:17 Page 9 of 10
http://www.biomedcentral.com/1472-6874/12/17users. The SNP is situated in region 8q24 that contains
no known genes but is in close proximity to FAM84B
(coding for a breast cancer membrane associated pro-
tein) and the proto-oncogene MYC. The 8q24 locus has
previously been reported to associate with other types of
cancer in addition to breast cancer [22] and to be more
strongly associated with ER + than ER- tumours [23].
Since the first GWAS on breast cancer was published
in 2007 several replication and interaction studies of
varying sizes have been published [24-27]. In 2010, a
large interaction study comprising 7610 breast cancer
cases from the Million Women Study in UK was under-
taken and potential interactions between 12 different
SNPs and 10 different variables (including height, BMI
and HRT) were tested [10]. This study did not find (con-
trary to previous suggestions) any significant gene-
environment interactions. Our study originally included
ten of the same polymorphisms as in the Million
Women Study (excluding rs1982073 in TGFB1 and
rs1800054 in ATM), but also included one additional
SNP from Easton et al. [1] and two additional SNPs
from our own candidate CpG study [11] (rs7766585 and
rs851987 both in ESR1). Although our material is not as
large, our study is comprised of three well described
study-populations, two of which were prospectively fol-
lowed for breast cancer incidence using the comprehen-
sive, population-based Swedish Cancer Registry [28].
Thus, our complete case ascertainment and ability to se-
lect matched controls from the same study base is likely
to have resulted in low risk for selection biases. How-
ever, the intervals between data collection, blood
sampling, and diagnosis differ substantially between the
three different study populations, something that might
be considered a limitation of the study.
Considering demographic traits, participants in the
MDCS have a slightly higher socioeconomic status than
the general population, but as this selection is the same
for the study base from which cases and controls are
derived, it should not affect the validity of our study [13].
MDCS participants were recruited at age 45–65 years.
The exclusion of prevalent cases removes early breast
cancer cases from this population. While the NHSDS
participants were primarily included from age 40 and
upwards, mammography screening had identified some
cases as young as 27 years. In Iceland prevalent cases of
breast cancer were recruited at varying times after diag-
nosis, resulting in an exclusion of early lethal cases and
older women with other causes of death. As the Ice-
landic controls were collected later and from the
same sample population as the cases there is the pos-
sibility of selection bias. Another limitation of our study
is the fact that HRT is reported only once (at recruitment)
without information about duration. We also lacked
information about other risk factors than age, height,BMI, HRT and therefore could not adjust our results for
other potential confounders.
Conclusions
Our evaluation of genetic predisposition for breast can-
cer in relation to three different environmental risk fac-
tors found no significant gene-environment interactions.
We did find tendencies for certain SNPs to exert an
effect on breast cancer risk only in women with certain
phenotypes. In particular the potential interaction be-
tween height and rs851987 in ESR1 in relation to breast
cancer risk could merit further investigation. However,
independent studies with many more cases would be
needed to verify this finding.
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